United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News BRENZAVVY proves effective in TheracosBio’s Phase 3 Type 2 diabetes study TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin’s effectiveness as an adjunct to… byPallavi MadhirajuAugust 4, 2023